. The ipsilateral ACA did not fill with contrast material from the left carotid artery injection (Fig. 1B) . Left oblique MR angiography views revealed a shelf of an atherosclerotic plaque in the cavernous segment of the left ICA (Fig. 2) . A 5000-U heparin bolus was administered intravenously to achieve an activated coagulation time of 300 seconds.
A No. 6 French Envoy guiding catheter (Cordis Neurovascular Systems, Miami Lakes, FL) was advanced over a 0.035-in Terumo Glidewire (Boston Scientific Meditech) into the distal left cervical ICA. The catheter was connected to a continuous heparinized saline flush. The lesion was crossed with a Prowler 14 microcatheter (Cordis Neurovascular Systems) over a 0.014-in Transcend wire (Boston Scientific Target, Fremont, CA). The microcatheter was advanced to the M 1 segment of the MCA, and the Transcend wire was removed. The injection of contrast material through the microcatheter allowed us to confirm its intraluminal position. A Balance Light Weight exchange wire (Guidant, Temecula, CA) was introduced through the microcatheter to provide better support for delivery of the balloon catheter. Angioplasty was performed with a 3 ϫ 10-mm Open Sail coronary balloon (Guidant) at 8 atm for 30 seconds, after which improvement of the vessel lumen was observed. Nevertheless, a direct CCF had formed at the proximal aspect of the atherosclerotic lesion in the C-5 segment of the cavernous ICA (Fig. 3A) . In an attempt to treat the fistula, a 4 ϫ 15-mm S7 coronary stent (Medtronic AVE, Santa Rosa, CA) was advanced over the exchange wire but would not cross the lesion because of the curvature of the artery. The stent was carefully withdrawn into the guiding catheter and removed. A 3.5 ϫ 9-mm S670 coronary stent (Medtronic AVE) was advanced over the exchange wire and successfully deposited across the lesion, and the CCF resolved (Fig. 3B) . The patient did not develop a neurological deficit. Left ICA angiography revealed contrast material filling the ipsilateral and contralateral ACA and MCA, which was not observed before angioplasty and stent placement (Fig. 3C) .
Postprocedure Course. After the procedure, the patient continued to receive clopidogrel (75 mg/day) for 30 days and will continue aspirin therapy (325 mg/day) indefinitely.
The patient was discharged home on the 2nd day after the procedure, and he remained asymptomatic at the 3-month follow-up evaluation.
Discussion
Atherosclerotic stenosis of large intracranial arteries accounts for 5 to 10% of ischemic strokes in the US. In retrospective studies it has been suggested that the annual risk of stroke in patients with intracranial stenosis is in the range of 3 to 15%. 2, 15 In the prospective Extracranial-Intracranial Bypass Study, recurrent strokes or TIAs occurred in the medical treatment group at a rate of 11.7% per year in patients with symptomatic MCA stenosis or occlusion during the 42-month follow-up period. 7 Currently, it is not clear which antithrombotic therapy is most effective for symptomatic intracranial stenosis.
In our patient, other antiplatelet agents such as thienopyridine derivatives (clopidogrel and ticlopidine) or dipyridamole could have been prescribed first, with angioplasty reserved until such time as his symptoms became refractory to this therapy. Studies have demonstrated the superiority of clopidogrel, ticlopidine, and dipyridamole over aspirin in reducing the risk of stroke and other vascular events among patients with previous stroke and TIA. 8, 17 These studies, however, have not specifically evaluated the population with symptomatic intracranial stenosis.
Another alternative therapy in our patient would have been warfarin; however, it is still not clear whether warfarin is superior to aspirin in patients with symptomatic intracranial stenosis. A prospective, randomized, double-blind clinical trial (the Warfarin-Aspirin Symptomatic Intracranial Disease trial) is underway to determine whether warfarin (international normalized ratio 2:3) or aspirin (1300 mg/ day) is more effective for preventing stroke and vascular occlusion-related death in patients with symptomatic intracranial large artery stenosis (50-99%). 15 Despite the available medical treatment, a significant proportion of patients with symptomatic intracranial stenosis continue to have recurrent TIAs or strokes. In a retrospective study, Thijs and Albers 14 reported a 56% risk of recurrent TIA or stroke in patients with symptomatic intracranial stenosis treated with antithrombotic agents. We performed angioplasty because of the high likelihood of stroke in our pa- tient, who was receiving 81 mg of aspirin per day. The complication in our case underscores the controversy surrounding the selection of patients for intracranial angioplasty.
Our case illustrates the technological limitations of balloon angioplasty in the treatment of intracranial stenosis. We selected a balloon size that was smaller than the normal diameter of the cavernous ICA proximal or distal to the stenosis. The balloon was inflated slowly with an insufflator over a period of 30 seconds. Despite these maneuvers, perforation of the artery developed, with subsequent CCF formation. In our case, the CCF was relatively small with slow flow, and we observed no significant pseudoaneurysm or varix of the cavernous sinus. As a result, we could have left the CCF alone because spontaneous closure of CCFs does occur, although it is more common in indirect fistulas.
An alternative endovascular treatment of the CCF in our case would include an intraarterial approach with balloon or coil occlusion of the fistula. Transvenous occlusion of the cavernous sinus with a silicone balloon and platinum microcoils is another option, although it can be a lengthy and costly procedure. We elected to treat the CCF with a highly flexible coronary stent that would allow navigation into a tortuous segment of the ICA and divert the shear stress of the blood into the fistula site. We believed that such a hemodynamic change might promote closure of the fistula. The S670 coronary stent is more flexible than the S7 stent. In addition, the shorter and smaller profile of the S670 device may have allowed its navigation into the cavernous segment of the ICA. We did not believe that direct stent placement over the cavernous lesion without initial angioplasty was possible because of the severe stenosis and curvature of the cavernous ICA. If the stent had failed to occlude the fistula, we would have observed the patient and considered the aforementioned options if needed. This is not the first case of CCF that has been treated with stent placement. Kocer, et al., 9 have reported the use of the polytetrafluoroethylene-covered Jostent (Jomed International, Helsingborg, Sweden) to treat a CCF that resulted from an injury to the ICA during a transsphenoidal surgery for pituitary adenoma. The long-term patency of covered stents is unknown, and this device was not available to us at the time of our procedure. In addition, Weber, et al., 16 have reported a cure of a direct CCF by using two detachable silicone balloons and a porous ACS multilink coronary stent (Guidant, Temecula, CA). In this case, intraoperative manipulation of a Fogarty catheter during surgical thromboendarterectomy of the ICA caused the CCF. To our knowledge, our case represents the first angioplasty-related CCF.
Conclusions
Intracranial angioplasty for symptomatic stenosis is not benign. The endovascular surgeon must be prepared to deal with complications of this procedure. Further experience is needed to evaluate the durability and suitability of intracranial angioplasty and stent placement in the treatment of symptomatic intracranial stenosis.
